{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:30:56Z","timestamp":1779341456748,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cct.2024.107697","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T21:53:10Z","timestamp":1726609990000},"page":"107697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control"],"prefix":"10.1016","volume":"146","author":[{"given":"Carol J.","family":"Fabian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh Pal","family":"Mudaranthakam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onalisa","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy E.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa D.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Nye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandy R.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Ranallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L.","family":"Kreutzjans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Altman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trina","family":"Metheny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Zelenchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry S.","family":"Komm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce F.","family":"Kimler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2024.107697_bb0005","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/AOG.0b013e318214f0de","article-title":"Duration of menopausal hot flushes and associated risk factors","volume":"117","author":"Freeman","year":"2011","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.cct.2024.107697_bb0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2024.107697_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/1940-6207.CAPR-17-0281","article-title":"What factors influence decision-making about breast cancer chemoprevention among high-risk women?","volume":"10","author":"Crew","year":"2017","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.cct.2024.107697_bb0020","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10549-018-4775-1","article-title":"Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews","volume":"170","author":"Hackett","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.cct.2024.107697_bb0025","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2024.107697_bb0030","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2024.107697_bb0035","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2024.107697_bb0040","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2024.107697_bb0045","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","article-title":"Patient reluctance toward tamoxifen use for breast cancer primary prevention","volume":"8","author":"Port","year":"2001","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cct.2024.107697_bb0050","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.cct.2024.107697_bb0055","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.cct.2024.107697_bb0060","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.19.01472","article-title":"Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update","volume":"37","author":"Visvanathan","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cct.2024.107697_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171189","article-title":"Sources of information influencing the state-of-the-science gap in hormone replacement therapy usage","volume":"12","author":"Chew","year":"2017","journal-title":"PLoS One"},{"issue":"10204","key":"10.1016\/j.cct.2024.107697_bb0070","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2024.107697_bb0075","doi-asserted-by":"crossref","DOI":"10.7326\/M19-0274","article-title":"Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: A randomized trial","author":"Manson","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.cct.2024.107697_bb0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2024.107697_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsbmb.2013.10.011","article-title":"Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action","volume":"142","author":"Bhavnani","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.cct.2024.107697_bb0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/me.2008-0366","article-title":"Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination","volume":"23","author":"Berrodin","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.cct.2024.107697_bb0095","first-page":"4559","article-title":"Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast","volume":"84","author":"Hofseth","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1\u20132","key":"10.1016\/j.cct.2024.107697_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10911-015-9339-y","article-title":"Impact of progesterone on stem\/progenitor cells in the human breast","volume":"20","author":"Hilton","year":"2015","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.cct.2024.107697_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2019.108503","article-title":"Molecular mechanisms underlying progesterone receptor action in breast cancer: insights into cell proliferation and stem cell regulation","volume":"152","author":"Cenciarini","year":"2019","journal-title":"Steroids"},{"issue":"1\u20132","key":"10.1016\/j.cct.2024.107697_bb0110","first-page":"171","article-title":"Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens","volume":"118","author":"Chang","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.cct.2024.107697_bb0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/mol.115.100925","article-title":"The dual estrogen receptor \u03b1 inhibitory effects of the tissue-selective estrogen complex for endometrial and breast safety","volume":"89","author":"Han","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cct.2024.107697_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.steroids.2014.06.004","article-title":"Development of conjugated estrogens\/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss","volume":"90","author":"Komm","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.cct.2024.107697_bb0125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/GME.0000000000001095","article-title":"Tissue selective estrogen complex (TSEC): a review","volume":"25","author":"Pickar","year":"2018","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.cct.2024.107697_bb0130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/13697137.2012.696289","article-title":"Bazedoxifene\/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention","volume":"15","author":"Pinkerton","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.cct.2024.107697_bb0135","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/GME.0000000000000688","article-title":"Timing and persistence of effect of conjugated estrogens\/bazedoxifene in postmenopausal women","volume":"23","author":"Kagan","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.cct.2024.107697_bb0140","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/GME.0b013e318252e46d","article-title":"Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys","volume":"19","author":"Ethun","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.cct.2024.107697_bb0145","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1210\/en.2012-1583","article-title":"Effects of the conjugated equine estrogen\/bazedoxifene tissues elective estrogen complex (TSEC) on mammary gland and breast cancer in mice","volume":"153","author":"Song","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.cct.2024.107697_bb0150","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ijc.31401","article-title":"Effect of a tissue selective estrogen complex on breast cancer: role of unique properties of conjugated equine estrogen","volume":"143","author":"Yue","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.cct.2024.107697_bb0155","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/GME.0000000000002217","article-title":"Comparative safety of conjugated estrogens\/bazedoxifene versus estrogen\/progestin combination hormone therapy among women in the United States: a multidatabase cohort study","volume":"30","author":"Hoffman","year":"2023","journal-title":"Menopause"},{"key":"10.1016\/j.cct.2024.107697_bb0160","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1940-6207.CAPR-19-0315","article-title":"Effect of bazedoxifene and conjugated estrogen (Duavee) on breast cancer risk biomarkers in high-risk women: a pilot study","volume":"12","author":"Fabian","year":"2019","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.cct.2024.107697_bb0165","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1158\/1055-9965.EPI-13-1219","article-title":"Automated measurement of volumetric mammographic density: a tool for widespread breast cancer risk assessment","volume":"23","author":"Brand","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"10","key":"10.1016\/j.cct.2024.107697_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110690","article-title":"Area and volumetric density estimation in processed full-field digital mammograms for risk assessment of breast cancer","volume":"9","author":"Cheddad","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2024.107697_bb0175","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/0008-5472.CAN-15-1927","article-title":"The proliferative activity of mammary epithelial cells in normal tissue predicts breast cancer risk in premenopausal women","volume":"76","author":"Huh","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.cct.2024.107697_bb0180","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0002-9440(10)64879-1","article-title":"Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression","volume":"160","author":"Shaaban","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cct.2024.107697_bb0185","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/jnci\/djh336","article-title":"Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women","volume":"96","author":"Missmer","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.cct.2024.107697_bb0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3645","article-title":"Association of circulating progesterone with breast cancer risk among postmenopausal women","volume":"3","author":"Trabert","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.cct.2024.107697_bb0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-0034-1395606","article-title":"Sex hormone binding globulin and risk of breast cancer in postmenopausal women: a meta-analysis of prospective studies","volume":"47","author":"He","year":"2015","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.cct.2024.107697_bb0200","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1470-2045(10)70095-4","article-title":"Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies","volume":"11","author":"Key","year":"2010","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.cct.2024.107697_bb0205","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1158\/1055-9965.EPI-10-1150","article-title":"Volume of mammographic density and risk of breast cancer","volume":"20","author":"Shepherd","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.cct.2024.107697_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099317","article-title":"Association between insulin resistance and breast carcinoma: a systematic review and meta-analysis","volume":"9","author":"Hernandez","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2024.107697_bb0215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.molmet.2013.12.009","article-title":"Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice","volume":"3","author":"Kim","year":"2014","journal-title":"Mo.l Metab."},{"issue":"4","key":"10.1016\/j.cct.2024.107697_bb0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/EJE-20-0619","article-title":"Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women","volume":"183","author":"Marlatt","year":"2020","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.cct.2024.107697_bb0225","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1148\/radiol.2016152062","article-title":"Breast cancer risk and mammographic density assessed with semiautomated and fully automated methods and BI-RADS","volume":"282","author":"Jeffers","year":"2017","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.cct.2024.107697_bb0230","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-018-0932-z","article-title":"A comparison of five methods of measuring mammographic density: a case-control study","volume":"20","author":"Astley","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.cct.2024.107697_bb0235","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1148\/radiol.15141686","article-title":"Reliability of automated breast density measurements","volume":"275","author":"Anlonzo-Proulx","year":"2015","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.cct.2024.107697_bb0240","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/jnci\/djr079","article-title":"Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study","volume":"103","author":"Cuzick","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"17","key":"10.1016\/j.cct.2024.107697_bb0245","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1200\/JCO.20.02598","article-title":"Low-dose tamoxifen for mammographic density reduction: a randomized controlled trial","volume":"39","author":"Eriksson","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cct.2024.107697_bb0250","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1093\/oncolo\/oyac104","article-title":"Time to mammographic density decrease after exposure to tamoxifen","volume":"27","author":"B\u00e4cklund","year":"2022","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.cct.2024.107697_bb0255","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1055-9965.EPI-16-0882","article-title":"Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors","volume":"26","author":"Engmann","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.cct.2024.107697_bb0260","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/GME.0b013e318271f5e7","article-title":"Breast density changes in a randomized controlled trial evaluating bazedoxifene\/conjugated estrogens","volume":"20","author":"Harvey","year":"2013","journal-title":"Menopause"},{"issue":"1066","key":"10.1016\/j.cct.2024.107697_bb0265","doi-asserted-by":"crossref","first-page":"20160258","DOI":"10.1259\/bjr.20160258","article-title":"Volumetric breast density measurement: sensitivity analysis of a relative physics approach","volume":"89","author":"Lau","year":"2016","journal-title":"Br. J. Radiol."},{"issue":"3","key":"10.1016\/j.cct.2024.107697_bb0270","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr1683","article-title":"Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer","volume":"9","author":"Khan","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.cct.2024.107697_bb0275","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/95.11.779","article-title":"A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers","volume":"95","author":"Decensi","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.cct.2024.107697_bb0280","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1124\/dmd.109.030999","article-title":"In vitro metabolism, permeability, and efflux of bazedoxifene in humans","volume":"38","author":"Shen","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cct.2024.107697_bb0285","first-page":"1457","article-title":"Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values","volume":"12","year":"2003","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"12","key":"10.1016\/j.cct.2024.107697_bb0290","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/ejcn.2014.213","article-title":"In vivo precision of the GE lunar iDXA for the measurement of visceral adipose tissue in adults: the influence of body mass index","volume":"68","author":"Mellis","year":"2014","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.cct.2024.107697_bb0295","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.4065\/77.11.1159","article-title":"Pilot evaluation of gabapentin for treating hot flashes","volume":"77","author":"Loprinzi","year":"2002","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.cct.2024.107697_bb0300","first-page":"209","article-title":"Further psychometric property development of the menopause-specific quality of life questionnaire and development of a modified version","volume":"50","author":"Lewis","year":"2005","journal-title":"MENQOL Intervent. Question. Maturitas"},{"issue":"1","key":"10.1016\/j.cct.2024.107697_bb0305","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1186\/s13063-022-06930-5","article-title":"A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer","volume":"23","author":"Gajewski","year":"2022","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.cct.2024.107697_bb0310","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1310\/hpj4903-273","article-title":"Conjugated estrogens and bazedoxifene","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.cct.2024.107697_bb0315","author":"Breast Cancer Surveillance Consortium"},{"issue":"2","key":"10.1016\/j.cct.2024.107697_bb0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/13697137.2011.650656","article-title":"Executive summary of the stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging","volume":"15","author":"Harlow","year":"2012","journal-title":"Climacteric"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714424002805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714424002805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T01:08:06Z","timestamp":1730509686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714424002805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":64,"alternative-id":["S1551714424002805"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2024.107697","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2024.107697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107697"}}